Arianna J Zhang, Gretchen Ball, Melissa P Zundell, Rosario Agüero, Danielle Yee, Ali Shields, Christina Asare, Kristina Navrazhina, Winston Liu, Negar Foolad, Jeffery Kwock, Priyanka Tejwani, Hassan Hamade, Tarannum Jaleel, Daniel Butler, Nanette Silverberg, Leigh Nattkemper, Daniel M Siegel, Jerry Tan, Brian S Kim, Cecilia Larocca, Michi M Shinohara, Athena Ehlert, John Latella, Emma Guttman-Yassky, James G Krueger, Vibeke Strand, April W Armstrong, Joseph F Merola, Lourdes Perez-Chada, Alice B Gottlieb
{"title":"国际皮肤病结局测量（IDEOM）： 2023年年会报告","authors":"Arianna J Zhang, Gretchen Ball, Melissa P Zundell, Rosario Agüero, Danielle Yee, Ali Shields, Christina Asare, Kristina Navrazhina, Winston Liu, Negar Foolad, Jeffery Kwock, Priyanka Tejwani, Hassan Hamade, Tarannum Jaleel, Daniel Butler, Nanette Silverberg, Leigh Nattkemper, Daniel M Siegel, Jerry Tan, Brian S Kim, Cecilia Larocca, Michi M Shinohara, Athena Ehlert, John Latella, Emma Guttman-Yassky, James G Krueger, Vibeke Strand, April W Armstrong, Joseph F Merola, Lourdes Perez-Chada, Alice B Gottlieb","doi":"10.36849/jdd.8363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.</p><p><strong>Summary: </strong>The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting. J Drugs Dermatol. 2024;23(12):1114-1120. doi:10.36849/JDD.8363.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 12","pages":"1114-1120"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.\",\"authors\":\"Arianna J Zhang, Gretchen Ball, Melissa P Zundell, Rosario Agüero, Danielle Yee, Ali Shields, Christina Asare, Kristina Navrazhina, Winston Liu, Negar Foolad, Jeffery Kwock, Priyanka Tejwani, Hassan Hamade, Tarannum Jaleel, Daniel Butler, Nanette Silverberg, Leigh Nattkemper, Daniel M Siegel, Jerry Tan, Brian S Kim, Cecilia Larocca, Michi M Shinohara, Athena Ehlert, John Latella, Emma Guttman-Yassky, James G Krueger, Vibeke Strand, April W Armstrong, Joseph F Merola, Lourdes Perez-Chada, Alice B Gottlieb\",\"doi\":\"10.36849/jdd.8363\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.</p><p><strong>Summary: </strong>The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting. J Drugs Dermatol. 2024;23(12):1114-1120. doi:10.36849/JDD.8363.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"23 12\",\"pages\":\"1114-1120\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/jdd.8363\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/jdd.8363","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023. Workgroups in psoriatic disease, hidradenitis suppurativa, geriatric dermatology, connective tissue disease, vitiligo, itch, actinic keratosis, acne, and cutaneous T-cell lymphoma discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates since the 2022 annual meeting and their next steps as established during the 2023 IDEOM Annual Meeting. J Drugs Dermatol. 2024;23(12):1114-1120. doi:10.36849/JDD.8363.
期刊介绍：
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
